Celltrion

068270.KO

125.42 USD

-1.42

-1.12%

Overview

Last close

125.42 usd

Market cap

26.03B usd

52 week high

176.66 usd

52 week low

97.64 usd

Target price

165.92 usd

Valuation

P/E

N/A

Forward P/E

24.6305

Price/Sales

17.3165

Price/Book Value

2.2195

Enterprise Value

27.40B usd

EV/Revenue

17.837

EV/EBITDA

41.8968

Key financials

Revenue TTM

1.67B usd

Gross Profit TTM

797.97M usd

EBITDA TTM

581.70M usd

Earnings per Share

N/A usd

Dividend

0.36 usd

Total assets

14.97B usd

Net debt

N/A usd

About

Celltrion, Inc., together with its subsidiaries, develops and produces drugs based on proteins for the treatment of oncology in South Korea. The company markets bio pharmaceuticals; generic pharmaceuticals; and covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 that is in phase 3 clinical trial for the treatment of asthma and urticaria; CT-P41, which is in phase 3 clinical trial for the treatment of osteoporosis and bone loss; CT-P42, which is in phase 3 clinical trial for the treatment of diabetic macular edema; and CT-P43 that is in phase 3 clinical trial for the treatment of psoriasis, crohn's disease, and ulcerative colitis. The company also offers CT-P47, which is in phase 3 clinical trial for the treatment of rheumatoid arthritis; and CT-P53 that is is in phase 3 clinical trial for the treatment of multiple sclerosis. Celltrion, Inc. was founded in 2002 and is headquartered in Incheon, South Korea.